Table 1:
Characteristics of study population subdivided by Mayo Adhesive Probability scores.
| MAP score, n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Covariate | 0 (n = 14) | 1 (n = 3) | 2 (n = 22) | 3 (n = 36) | 4 (n = 31) | 5 (n = 35) | Total (n = 141) | P |
| Gender | ||||||||
| Male | 9 (64.3) | 1 (33.3) | 14 (63.6) | 19 (52.8) | 26 (83.9) | 31 (88.6) | 100 (70.9) | 0.006 |
| Female | 5 (35.7) | 2 (66.7) | 8 (36.4) | 17 (47.2) | 5 (16.1) | 4 (11.4) | 41 (29.1) | |
| Race | ||||||||
| White | 7 (50) | 1 (33.3) | 15 (68.2) | 28 (77.8) | 25 (80.6) | 28 (80) | 104 (73.8) | 0.12 |
| Non-white | 7 (50) | 2 (66.7) | 7 (31.8) | 8 (22.2) | 6 (19.4) | 7 (20) | 37 (26.2) | |
| IVC thrombus | 5 (35.7) | 0 (0) | 11 (50) | 17 (47.2) | 18 (58.1) | 14 (40) | 65 (46.1) | 0.343 |
| ECOG | ||||||||
| ≥1 | 0 (0) | 1 (33.3) | 5 (22.7) | 14 (38.9) | 8 (25.8) | 5 (14.3) | 33 (23.4) | 0.052 |
| BMI* | 23.9 (20.1–29.0) | 30.0 (28.6–31.0) | 29.0 (24–35) | 26.0 (23.1–30.3) | 28.8 (26.2–32.9) | 29.9 (27–34.3) | 28.50 (24.6–32.6) | 0.059 |
| Age* | 54.2 (44.2–68.1) | 62.7 (51.2–77.7) | 59.4 (45.6–71.6) | 61.6 (51.5–71.3) | 66.9 (55.4–73.4) | 63.3 (54.5–73.4) | 62.7 (53.8–71.5) | 0.212 |
| Nephrectomy side | ||||||||
| Right | 8 (57.1) | 0 (0) | 12 (54.5) | 16 (44.4) | 17 (54.8) | 19 (54.3) | 72 (51.1) | 0.494 |
| Histology | ||||||||
| ccRCC | 6 (42.9) | 2 (66.7) | 14 (63.6) | 32 (88.9) | 24 (77.4) | 29 (82.9) | 107 (75.9) | 0.012 |
| non-ccRCC | 8 (57.1) | 1 (33.3) | 8 (36.4) | 4 (11.1) | 7 (22.6) | 6 (17.1) | 34 (24.1) | |
| pT stage | ||||||||
| T3 | 11 (78.6) | 3 (100) | 22 (100) | 35 (97.2) | 30 (96.8) | 33 (94.3) | 134 (95.0) | 0.077 |
| T4 | 3 (21.4) | 0 (0) | 0 (0) | 1 (2.8) | 1 (3.2) | 2 (5.7) | 7 (5.0) | |
| pN stage | ||||||||
| N1 | 2 (14.3) | 0 (0) | 2 (9.1) | 4 (11.1) | 5 (16.1) | 2 (6.3) | 15 (10.9) | 0.821 |
| Fuhrman nuclear grade | ||||||||
| 2 | 0 (0) | 2 (66.7) | 4 (18.2) | 3 (8.3) | 6 (19.4) | 5 (14.3) | 20 (14.2) | 0.246 |
| 3 | 8 (57.1) | 1 (33.3) | 11 (50) | 22 (61.1) | 15 (48.4) | 16 (45.7) | 73 (51.8) | |
| 4 | 6 (42.9) | 0 (0) | 7 (31.8) | 11 (30.6) | 10 (32.3) | 14 (40) | 48 (34.0) | |
| Necrosis | ||||||||
| Yes | 10 (71.4) | 2 (66.7) | 17 (77.3) | 24 (66.7) | 17 (54.8) | 24 (68.6) | 94 (66.7) | 0.659 |
| SSIGN score*** | ||||||||
| n (%) | 6 (5.6) | 2 (1.8) | 14 (13.08) | 32 (29.9) | 24 (22.4) | 29 (27.1) | 107 (100) | |
| Mean (std) | 7.3 (±1.8) | 3.5 (±2.1) | 5.1 (±1.6) | 6.1 (±1.7) | 6.3 (±1.8) | 6 (±1.6) | 6 (±1.76) | |
| UISS score** | 2.5 (±0.9) | 2 (±0.6) | 4 (±1.0) | 3 (±0.9) | 3.5 (±0.9) | 2 (± 1.0) | 2.94 (±0.93) | 0.57 |
| mGPS | ||||||||
| Low | 8 (66.7) | 2 (100) | 8 (38.1) | 13 (38.2) | 13 (44.8) | 12 (35.3) | 56 (42.4) | 0.211 |
| Intermediate | 2 (16.7) | 0 (0) | 4 (19) | 7 (20.6) | 9 (31) | 14 (41.2) | 36 (27.3) | |
| High | 2 (16.7) | 0 (0) | 9 (42.9) | 14 (41.2) | 7 (24.1) | 8 (23.5) | 40 (30.3) | |
| Missing | – | – | – | – | – | – | 9 (6.4%) | |
| Corrected calcium** | 9.8 (±0.6) | 9.8 (±0.6) | 9.9 (±0.7) | 9.8 (±0.8) | 9.7 (±0.6) | 9.6 (±0.4) | 9.74 (±0.65) | 0.447 |
| Received systemic therapy | 4 (28.6) | 0 (0) | 6 (27.3) | 12 (33.3) | 14 (45.2) | 11 (31.4) | 47 (33.3) | 0.547 |
| MAP score | ||||||||
| Mean** | – | – | – | – | – | – | 3.22 (±1.52) | |
| 0–3 | – | – | – | – | – | – | 75 (53.2) | |
| 4–5 | – | – | – | – | – | – | 66 (46.8) | |
MAP, Mayo Adhesive Probability; n, number; IVC, Inferior Vena Cava; ECOG, Eastern Cooperative Oncology Group; BMI, Body mass index; SSIGN, Stage, Size, Necrosis, Grade; ccRCC, Clear-cell renal cell carcinoma; UISS, UCLA Integrated Staging System; mGPS, modified Glasgow prognostic score. *Median (IQR), **Mean (standard deviation[std]), ***non-ccRCC not included (n = 34).